RxDoctor Payments Data

Sami Roumani, MD

Family Medicine · Milwaukee, WINPI 1306936414

Payments from drug & device makers

$474in general payments, 2019–2025

Across 26 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$217
  • Gen-probe Sales & Service, Inc.$130
  • Inari Medical, Inc.$35
  • GSK$25
  • Pfizer$25
  • Novartis$24
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$474100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sunovion Pharmaceuticals Inc.19$217
Gen-probe Sales & Service, Inc.1$130
Inari Medical, Inc.1$35
GSK1$25
Pfizer2$25
Novartis1$24
AstraZeneca1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$474 in reported general payments places this provider in the 80th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$24,868
Medicare patients
102
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$58,103
XareltoRivaroxaban24$11,459
Breo ElliptaFluticasone/Vilanterol19$10,342
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,507
MyrbetriqMirabegron17$8,851
NamzaricMemantine Hcl/Donepezil Hcl26$7,663
ArexvyRsvpref3 Antigen/As01e/Pf20$6,377
BrilintaTicagrelor13$5,875
Ropinirole ErRopinirole Hcl12$4,744
Pantoprazole Sodium201$3,263
Potassium Chloride172$3,000
Levothyroxine Sodium222$2,937
Midodrine Hcl46$2,739
Atorvastatin Calcium224$2,641
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc27$2,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$58,103142 claims
GSKBreo Ellipta, Trelegy Ellipta, Arexvy$25$26,22753 claims
AstraZenecaBrilinta$19$5,87513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →